These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

156 related items for PubMed ID: 4035368

  • 1. Biologic studies on chemically synthesized pentasaccharide and tetrasaccharide fragments.
    Choay J.
    Semin Thromb Hemost; 1985 Apr; 11(2):81-5. PubMed ID: 4035368
    [Abstract] [Full Text] [Related]

  • 2. Antifactor Xa activity and antithrombotic activity in rats of structural analogues of the minimum antithrombin III binding sequence: discovery of compounds with a longer duration of action than of the natural pentasaccharide.
    Meuleman DG, Hobbelen PM, Van Dinther TG, Vogel GM, Van Boeckel CA, Moelker HC.
    Semin Thromb Hemost; 1991 Apr; 17 Suppl 1():112-7. PubMed ID: 2068564
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Pharmacological profile of the chemically synthesized antithrombin III binding fragment of heparin (pentasaccharide) in rats.
    Hobbelen PM, van Dinther TG, Vogel GM, van Boeckel CA, Moelker HC, Meuleman DG.
    Thromb Haemost; 1990 Apr 12; 63(2):265-70. PubMed ID: 2363127
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Structure-activity relationship in heparin: a synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-factor Xa activity.
    Choay J, Petitou M, Lormeau JC, Sinaÿ P, Casu B, Gatti G.
    Biochem Biophys Res Commun; 1983 Oct 31; 116(2):492-9. PubMed ID: 6651824
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Effects of heparin oligosaccharides with high affinity for antithrombin III in experimental venous thrombosis.
    Thomas DP, Merton RE, Barrowcliffe TW, Thunberg L, Lindahl U.
    Thromb Haemost; 1982 Jun 28; 47(3):244-8. PubMed ID: 7112499
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. A synthetic antithrombin III binding pentasaccharide is now a drug! What comes next?
    Petitou M, van Boeckel CA.
    Angew Chem Int Ed Engl; 2004 Jun 14; 43(24):3118-33. PubMed ID: 15199558
    [Abstract] [Full Text] [Related]

  • 14. Molecular weight of heparin versus biologic activity. Some additional considerations.
    Losito R, Losito C.
    Semin Thromb Hemost; 1985 Jan 14; 11(1):29-33. PubMed ID: 2579437
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Antithrombotic effects of synthetic pentasaccharide with high affinity for plasma antithrombin III in non-human primates.
    Cadroy Y, Hanson SR, Harker LA.
    Thromb Haemost; 1993 Oct 18; 70(4):631-5. PubMed ID: 8115989
    [Abstract] [Full Text] [Related]

  • 17. The oligosaccharide side chain on Asn-135 of alpha-antithrombin, absent in beta-antithrombin, decreases the heparin affinity of the inhibitor by affecting the heparin-induced conformational change.
    Turk B, Brieditis I, Bock SC, Olson ST, Björk I.
    Biochemistry; 1997 Jun 03; 36(22):6682-91. PubMed ID: 9184148
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.